Clinical investigation conducted by Withings to assess the accuracy of its scale in identifying cases of small fiber neuropathy

Withings is ready to begin clinical research to see whether or not its recently introduced smart scale can detect tiny fiber neuropathy. The company just unveiled this screening ability.

ClinicalTrials.gov included information about the test, which lasted for five months. It is scheduled to start on March 20 and continue through August 20 of this year. To determine whether or not the Withings scale “WBS08” can detect small fiber neuropathy, the research hopes to enlist the participation of 177 people. Even though the scale in question is not specifically mentioned, this is likely a reference to the one that was introduced at CES 2022 at the beginning of January.

The Withings Body Scan is designed to be the most innovative bathroom scale now available for purchase to refresh your memory. According to the promotional materials, it will be able to monitor segmental body composition, analyze nerve activity, and detect Afib in addition to the standard weight metrics.

The topmost portion of the scale features a handle that can be retracted to accomplish this. While you are standing on this, you are expected to have a firm grip on it. In addition to the two electrodes located in the main body of the scale, there are also two electrodes located in the scale’s handle, as well as four weight sensors and 14 ITP electrodes.

Keeping an eye out for signs of small fiber neuropathy

During the month of January, Withings also made the announcement that it had purchased Impeto Medical. This company focuses on researching, developing, manufacturing, and marketing various medical equipment to medical professionals. Small fiber neuropathy refers to damage or dysfunction of small fibers of the peripheral nervous system. Their claim to fame is a set of standards called SUDOSCAN technology that has been certified by the FDA and is used to diagnose and track cases of small fiber neuropathy. These are the fibers in the skin that are responsible for detecting things like pain, health, and itching.

The majority of persons who are given this diagnosis have a moderate form of the disorder and do not have significant neurological impairments or disabilities as a result of their condition. On the other hand, it is not uncommon for these patients to also be suffering from additional underlying health conditions, such as diabetes, Sjogren’s syndrome, or lupus. A person’s overall health and life expectancy may suffer as a result of small fiber neuropathy, which is linked to an increased risk of cardiovascular issues.

The French company is about to begin clinical testing to see whether or not the technology integrated into its smart scale is effective. Participants in the study will either be diagnosed with diabetes or neuropathy or both of these conditions. Throughout the course of the study, they will be expected to perform routine checks using the Withings scale and the Sudoscan to assess how they are faring with the condition. The primary purpose of this investigation is to ascertain the “diagnostic performance of the Withings WBS08” by “utilizing the sensitivity and the specificity for an electrochemical skin conductance threshold (moderate dysfunction and severe dysfunction).”

The Withings Body Scan scale, which costs $299, is not yet available for purchase. The second half of 2022 is now anticipated to be the release date, presuming FDA approval. Taking into account that the research is scheduled to be finished in August, it follows that September or October is a possibility for the debut date. When it eventually becomes available, we will make every effort to get our hands and feet on it so that we can write a comprehensive evaluation of it.

Leave a Reply